# Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

> **NCT02532400** · PHASE3 · TERMINATED · sponsor: **Ruijin Hospital** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant endocrine therapy
- **DRUG:** Neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT02532400
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Hard to enroll expected number of eligible patients.
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532400, "Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT02532400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*